MARKET

THMO

THMO

Thermogenesis Holdings Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3450
-0.0352
-9.26%
Closed 19:19 05/20 EDT
OPEN
0.4000
PREV CLOSE
0.3802
HIGH
0.4100
LOW
0.3405
VOLUME
52.41K
TURNOVER
--
52 WEEK HIGH
3.160
52 WEEK LOW
0.3104
MARKET CAP
4.43M
P/E (TTM)
-0.3580
1D
5D
1M
3M
1Y
5Y
BRIEF-Thermogenesis Holdings Announces Financial Results For The First Quarter Ended March 31, 2022 And Provides Corporate Update
reuters.com · 3d ago
ThermoGenesis GAAP EPS of -$0.16, revenue of $2.66M
ThermoGenesis press release (NASDAQ:THMO): Q1 GAAP EPS of -$0.16. Revenue of $2.66M (+75.0% Y/Y).
Seekingalpha · 3d ago
ThermoGenesis Holdings Q1 EPS $(0.16) Misses $0.02 Estimate, Sales $2.70M May Not Compare To $5.60M Estimate
ThermoGenesis Holdings (NASDAQ:THMO) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $0.02 by 900 percent. This is a 40.74 percent increase over losses of $(0.27) per share
Benzinga · 3d ago
The Daily Biotech Pulse: Valneva's COVID-19 Vaccine Filing Accepted By EMA, Enanta's RSV Candidate Fails, Orphan Drug Tag For Mersana's Gastric Cancer Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 4d ago
Earnings Scheduled For May 19, 2022
  Companies Reporting Before The Bell • Sociedad Quimica Y Minera (NYSE:SQM) is projected to report quarterly earnings at $1.28 per share on revenue of $1.28 billion.
Benzinga · 4d ago
ThermoGenesis Holdings to Announce Financial Results for the First Quarter Ended March 31, 2022 and Provide a Corporate Strategic Update
ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the first quarter ended March 31, 2022 ...
PR Newswire · 5d ago
ThermoGenesis Holdings, Inc. (NASDAQ:THMO) About To Shift From Loss To Profit
We feel now is a pretty good time to analyse ThermoGenesis Holdings, Inc.'s ( NASDAQ:THMO ) business as it appears the...
Simply Wall St. · 05/15 14:58
YmAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Lags Revenue Estimates
YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 9.86% and 0.13%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/09 21:25
More
No Data
Learn about the latest financial forecast of THMO. Analyze the recent business situations of Thermogenesis Holdings Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average THMO stock price target is 6.00 with a high estimate of 6.00 and a low estimate of 6.00.
High6.00
Average6.00
Low6.00
Current 0.3450
EPS
Actual
Estimate
-0.30-0.22-0.14-0.06
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 25
Institutional Holdings: 470.48K
% Owned: 3.67%
Shares Outstanding: 12.83M
TypeInstitutionsShares
Increased
3
2.01K
New
2
41.56K
Decreased
5
10.73K
Sold Out
1
27
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Office Equipment
+0.54%
Technology Equipment
+1.66%
Key Executives
Chairman/President/Chief Executive Officer/Director
Xiaochun Xu
Chief Financial Officer
Jeffery Cauble
Independent Director
Debra Donaghy
Independent Director
Russell Medford
Independent Director
Joseph Thomis
No Data
No Data
About THMO
ThermoGenesis Holdings, Inc. develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company operates through two segments: Device Segment and Clinical Development Segment. It provides the AutoXpress and BioArchive platforms for automated clinical bio-banking, PXP platform for point-of-care cell-based therapies and CAR-TXpress platform for bio-manufacturing for immuno-oncology applications. It manufactures and markets three categories of products, Clinical Bio-Banking Applications, Point-of-Care Applications, and Large Scale Cell Processing and Biomanufacturing. Clinical Bio-Banking Applications includes AXP II Automated Cell Separation System, BioArchive Automated Cryopreservation System and PXP Point-of-Care System. Point-of-Care Applications includes PXP Point-of-Care System, PXP-LAVARE System and PXP-1000 System. Large Scale Cell Processing and Biomanufacturing includes X-Series Products and CAR-TXpress Platform.

Webull offers kinds of Thermogenesis Holdings Inc stock information, including NASDAQ:THMO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, THMO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading THMO stock methods without spending real money on the virtual paper trading platform.